What is PathoQuest?
PathoQuest is a specialized biotechnology firm that leverages next-generation sequencing (NGS) to provide advanced biosafety assays for the biopharmaceutical sector. The company's core value proposition lies in its ability to replace traditional, time-consuming animal-based testing methods with rapid, reliable, and ethical digital alternatives. By focusing on GMP-grade biotesting, PathoQuest ensures that biopharma companies can maintain rigorous safety and compliance standards throughout the development of complex biological products. Their service portfolio, which includes comprehensive genetic analysis and viral detection, serves as a cornerstone for companies navigating the complexities of modern therapeutic manufacturing.
How much funding has PathoQuest raised?
PathoQuest has raised a total of $13.8M across 2 funding rounds:
Unspecified
$5M
Other Financing Round
$8.8M
Unspecified (2013): $5M with participation from Kurma Partners, Idinvest Partners, and Aurinvest
Other Financing Round (2019): $8.8M led by Idinvest Partners, French Public Program Investissement D'Avenir, Norgine, Kurma Partners, investiere, and Charles River Labs
Key Investors in PathoQuest
Kurma Partners
A prominent European venture capital firm specializing in healthcare and biotechnology, focusing on investments ranging from pre-seed to growth capital.
Idinvest Partners
A Paris-based mid-market private equity firm that provides financial support and strategic guidance to entrepreneurs across various stages of business development.
Norgine
A leading European specialist pharmaceutical company with over a century of experience in bringing transformative medicines to patients.
What's next for PathoQuest?
With this recent capital injection, PathoQuest is well-positioned to scale its operational capacity and expand its footprint within the global biopharma ecosystem. The strategic focus will likely shift toward enhancing the throughput of their NGS platform and deepening their integration into the supply chains of major pharmaceutical manufacturers. By continuing to refine their diagnostic capabilities, the company aims to set a new industry standard for quality control, ultimately reducing the regulatory burden for developers of innovative therapies. As the industry moves toward more personalized and complex medicine, PathoQuest's data-driven approach to safety will remain a key differentiator in the competitive landscape of life sciences.
See full PathoQuest company page
